Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer
L Saltz, S Badarinath, S Dakhil, B Bienvenu… - Clinical colorectal …, 2012 - Elsevier
Background Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-
refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and
bevacizumab (B), and preliminary data of cetuximab+ bevacizumab, and toxicity profiles
suggests that FOLF-CB (5-FU, L, C+ B) may have activity with a favorable toxicity profile as
first-line therapy. Methods Eligible patients were randomized at registration to either arm A
(mFOLFOX6-B)(modified, 5-FU. L (folinic acid), oxaliplatin (O)+ bevacizumab), administered …
refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and
bevacizumab (B), and preliminary data of cetuximab+ bevacizumab, and toxicity profiles
suggests that FOLF-CB (5-FU, L, C+ B) may have activity with a favorable toxicity profile as
first-line therapy. Methods Eligible patients were randomized at registration to either arm A
(mFOLFOX6-B)(modified, 5-FU. L (folinic acid), oxaliplatin (O)+ bevacizumab), administered …
